Benefit Sharing and Intellectual Property: Who Owns the Value African Trials Create?
A clinical trial closes. Its samples and data may still have years of scientific life ahead. Stored specimens can support new investigations. Trial datasets can help researchers answer questions beyond the original protocol. Further analysis may contribute to a...
South-South Collaboration: What African Research Can Teach and Learn
A clinical trial conducted in Africa may recruit African participants, rely on African investigators and address a pressing African health need, yet still route its funding, protocol design, data governance and publication decisions through institutions thousands of...
Genomics and Precision Medicine: Why African Data Is Missing from the Global Map
The global precision medicine project has a foundational problem. The datasets on which it is being built do not represent the species they claim to serve. According to the GWAS Diversity Monitor, populations from the African continent account for approximately 0.16%...
Recruitment, Retention, and Representation: Africa’s Participant Diversity Problem
A clinical trial can reach its enrollment target and still produce evidence that is too narrow for the population it is intended to serve. The headline number may look reassuring, but it does not reveal whether the cohort reflects the relevant differences in age, sex,...
Advancing Africa-Led Research to Prevent Mother-to-Child HIV Transmission
Africa Clinical Research Network awarded grant to lead SUPPRESS-LA, a Phase 3 trial evaluating long-acting antiretroviral therapy to prevent mother-to-child HIV transmission Africa-led, multicountry study in South Africa, Uganda and Zimbabwe will evaluate whether...
The African Medicines Agency: What Continental Regulatory Harmonization Actually Changes
A multi-country clinical trial can follow one protocol, test one investigational product, and pursue one scientific question, yet encounter different submission formats, review requirements, amendment procedures, and decision timelines in every participating country. ...
Pharmacovigilance and Post-Market Surveillance: Africa’s Safety Blind Spot
A medicine may complete clinical trials with an acceptable safety profile and still reveal important risks only after thousands, or millions, of people begin using it. Approval is not the end of safety assessment. It is the point at which monitoring must expand from a...
Decentralized and Digital Trials: What’s Realistic in African Settings
A video consultation can replace a clinic visit. It cannot replace clinical judgment, reliable connectivity, regulatory oversight, or accountable data governance. That distinction is often blurred in discussions about decentralized clinical trials (DCTs). Remote...